**Supplementary Table S3.** Univariate and multivariate Cox regression analysis for recurrence in advanced NSCLC patients

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Variables | Univariate analysis | 　 | 　 | Multivariate analysis | 　 |
| 　 | 　 | HR (95% CI) | *P*-Value | 　 | HR (95% CI) | *P*-Value |
| Baseline information | 　 |  | 　 | 　 |  |
| 　 | Age (≥60 vs. <60) | 0.797 (0.549-1156) | 0.231 | 　 | 1.075 (0.702-1.644) | 0.740 |
| 　 | Gender (Male vs. Female) | 1.337 (0.874-2.043) | 0.180  | 　 | 2.061 (0.713-5.960) | 0.182 |
| 　 | Smoking history | 0.984 (0.657-1.474) | 0.939 | 　 | 1.703 (0.618-4.690) | 0.303 |
| 　 | Surgery treatment | 0.582 (0.337-1.004) | 0.052 | 　 | 0.618 (0.336-1.137) | 0.122 |
| 　 | ECOG performance status (0-1 vs. 2) | 1.372 (0.806-2.336) | 0.243  | 　 | 1.682 (0.913-3.098) | 0.095 |
| Clinical data | 　 | 　 | 　 | 　 | 　 |
| 　 | TNM classification (III vs. IV stage) | 5.933 (1.881-18.715) | 0.002\*\* | 　 | 4.098 (1.131-14.848) | 0.032\* |
| 　 | Tumor invasion | 1.453 (1.044-2.021) | 0.027\* | 　 | 1.114 (0.768-1.616) | 0.569 |
| 　 | Lymph node metastasis | 1.175 (0.750-1.840) | 0.483 | 　 | 0.906 (0.545-1.506) | 0.703 |
| 　 | Distant metastasis | 5.933 (1.881-18.715) | 0.002\*\* | 　 | 4.098 (1.131-14.848) | 0.032\* |
| 　 | Metastatic sites (≥3 vs. <3) | 2.171 (1.489-3.165) | <0.001\*\*\* | 　 | 1.661 (1.078-2.562) | 0.022\* |
| 　 | Brain metastasis | 1.6632 (1.144-2.416) | 0.008\*\* | 　 | 1.146 (0.950-1.383) | 0.095 |
| 　 | Liver metastases | 2.248 (1.521-3.323) | <0.001\*\*\* | 　 | 1.842 (1.172-2.895) | 0.008\*\* |
| 　 | Bone metastases | 1.860 (1.267-2.730) | 0.002\*\* | 　 | 1.174 (0.674-2.043) | 0.571 |
| Pathological characteristics | 　 | 　 | 　 | 　 | 　 |
| 　 | Histological subtype | 1.332 (0.891-1.991) | 0.162  | 　 | 0.876 (0.525-1.460) | 0.611 |
| 　 | PD-L1 TPS (Positive vs. Negative) | 1.097 (0.920-1.309) | 0.302  | 　 | 1.182 (0.966-1.446) | 0.104 |
| 　 | EGFR mutation status | 1.343 (0.823-2.190) | 0.238  | 　 | 1.616 (0.555-4.704) | 0.379 |
| 　 | EGFR mutation subtype | 1.288 (0.942-1.763) | 0.113 | 　 | 0.822 (0.485-1.394) | 0.467 |
| Past medical history | 　 | 　 | 　 | 　 | 　 |
| 　 | No. of prior systemic regimens (≥3 vs. <3) | 1.194 (1.015-1.405) | 0.033\* | 　 | 1.137 (0.937-1.378) | 0.193 |
| 　 | Previous thoracic radiation therapy | 0.658 (0.421-1.030) | 0.067 | 　 | 0.732 (0.439-1.220) | 0.232 |
| 　 | Previous antivascular drug therapy | 1.302 (0.843-2.013) | 0.234 | 　 | 1.053 (0.605-1.834) | 0.855 |
| Treatment strategies | 　 | 　 | 　 | 　 | 　 |
| 　 | A+P combination vs. Anlotinib | 0.777 (0.626-0.964) | 0.022\* | 　 | 0.759 (0.588-0.979) | 0.034\* |
| 　 | A+P combination vs. Immunotherapy | 0.507 (0.306-0.839) | 0.008\*\* | 　 | 0.516 (0.282-0.941) | 0.031\* |
| 　 | Anlotinib vs. Immunotherapy | 1.169 (0.729-1.876) | 0.517 | 　 | 0.798 (0.425-1.498) | 0.482 |

Abbreviations: *HR* hazard ratio, *CI* confidence interval, \**P*< 0.05, \*\**P*< 0.01, \*\*\**P*< 0.001